Navigation Links
NZymeCeuticals Announces the Introduction of New Bulk Ingredient 'Platinum Nattokinase' (PN20K) to Dietary Supplement Industry
Date:9/8/2008

NZymeCeuticals, Inc., (d/b/a NZyme) a company established in 2002, will begin to market "Platinum Nattokinase" (PN20K) Sept. 2008. Dr. Ralph E. Holsworth, President of NZymeCeuticals, Inc., announced Friday the company will begin to market the new line of bulk powder enzyme ingredient, nattokinase as "PN20K" to North and South America.

Durango, CO (PRWEB) September 8, 2008 -- "PN20K" is a pro-fibrinolytic enzyme that is extracted from a particular type of fermented soybean (natto) and renown in the dietary supplement industry and medical field for its "blood clot busting" abilities. "The new line has been in development for the past two years in Japan and establishes the 'platinum' standard for nattokinase." "PN20K is patent protected and manufactured by an ISO 9000 certified Japanese manufacturer," says Dr. Holsworth. A number of Japanese researchers and Dr. Holsworth collaborated on specific characteristics of nattokinase, enhancing the specificity of nattokinase's ability to breakup "cross-linked" fibrin and increasing its stability in clinical settings. In addition, PN20K significantly improves the way blood flows and enhances human microcirculation, promising novel therapeutic modalities for hypertension, coronary artery disease, diabetes, cerebrovascular accidents and deep vein thrombosis.

Dr. Holsworth first introduced nattokinase to the United States in 2002. Since then, the ingredient has gained much attention largely due to its naturally occurring "blood clot busting" ability. During this time, Dr. Holsworth and Dr. Sumi (the discoverer of nattokinase) have met several times in Japan and the USA to discuss the therapeutic properties of the enzyme and its future medical use. Over the years, Drs. Holsworth and Sumi continue to collaborate on the studies and findings of nattokinase. Initial research indicates PN20K has the potential to significantly impact cardiovascular diseases because of its ability to change chemical and physical characteristics of blood, providing a "one-two punch." "We simply don't see these positive effects with typical pharmaceutical drugs," says Dr. Holsworth.

In Japan, the enzyme has an annual 15 billion yen market. Since its introduction to the U.S. market, bulk sales for the enzyme have experienced increased growth and demand. With different manufacturers of nattokinase from all over the world, the activity, stability and purity of the product varies significantly. NZymeCeuticals' bulk ingredients undergo third-party testing for quality assurance and quality control as well as to preserving the integrity of the new ingredient. Clinical research using PN20K as the therapeutic agent is well underway.

http://www.nzymeceuticals.com

###

Read the full story at http://www.prweb.com/releases/nattokinase/holsworth/prweb1294934.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services
2. Z Trim Holdings, Inc. Announces Private Placement Funding
3. The Risk Management and Patient Safety Institute Announces Agreement With Pioneering Health Care Simulation Organization, PSO One
4. Cogdell Spencer Announces First Synergy Project in Pensacola, Florida
5. Conde Nast Media Group Announces Performance of Just Stand Up to be Fed Live from the Stage at FASHION ROCKS to ABC, CBS and NBCs Simultaneous Broadcast of Stand Up To Cancer Nationwide Fund-Raising Event On September 5th
6. LIFE Foundation Announces 2008 realLIFEstories Award Recipients to Illustrate Benefits of Life and Disability Insurance
7. Elbit Imaging Ltd. Announces Second Quarter Results for 2008
8. Custom Briefings Announces Launch of Endocrine Daily Briefing
9. Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss
10. Versus Technology Announces Third Quarter Results
11. Replidyne Announces Restructuring of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: